(firstQuint)Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain.

 This is an open-label safety and tolerability study in which approximately 600 subjects will receive NKTR-181 for up to 52 weeks.

 Subjects may include newly enrolled subjects and subjects who have recently completed SUMMIT-07 or SUMMIT-12 studies.

 This study will also investigate the pharmacokinetics of NKTR-181 in patients with chronic low back pain or chronic non-cancer pain.

.

 Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain@highlight

The purpose of this 52-week open label study is to determine the safety of a new opioid molecule, NKTR-181, in patients with moderate to severe chronic low back pain or chronic non-cancer pain.

